In contrast, Bcr–Abl-positive Lama84 cells were inhibited with an IC50 of approximately 62.5 nM, confirming the selective activity of imatinib in Bcr–Abl-positive CML cells. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.